Migraine Biotech Doses First Patient in Phase 2b EVO756 Trial
Myelofibrosis Combo Advances as Karyopharm Preps August sNDA
Sarepta Therapeutics Navigates FDA Hold on Elevidys in Expanding DMD Market
NY Telehealth Extension Advances Rocket Doctor AI Platform
PFAS Treatment System Processes 2 Million Gallons at New Jersey Site
This AI Healthcare Platform Is Taking Its New York Expansion Through 2029
Cleantech Company Delivers PFAS Removal Breakthrough in New Jersey
Evommune Doses First Patient in Migraine Trial
Evommune Inc. (EVMN:NYSE) dosed its first patient in a Phase 2b trial of EVO756, an oral migraine prevention drug targeting the MRGPRX2 receptor.Karyopharm Pursues Myelofibrosis FDA Milestone
Karyopharm Therapeutics Inc. (KPTI:NASDAQ) prepares an FDA filing for selinexor plus ruxolitinib after Phase 3 results, targeting the first approved combination therapy for myelofibrosis.Sarepta Grants New CEO 2.2M Stock Options Amid "Sell" Rating
Sarepta Therapeutics Inc. (SRPT:NASDAQ) granted CEO Michael Severino options for 2,224,342 shares and 756,104 RSUs as an inducement award tied to his hiring.Digital Health Firm Launches Integrated GLP-1 Program
DarioHealth integrates its digital platform with licensed providers to offer end-to-end GLP-1 support. See how the new program targets employers and health plans in a growing market.New GLP-1 Platform Combines Doctor Prescriptions, AI Coaching and Chronic Care
DarioHealth Corp. (NASDAQ: DRIO) introduced its Integrated GLP-1 Program, bringing licensed provider evaluations, FDA-approved GLP-1 prescribing where clinically appropriate and ongoing care into one experience.Dyadic C1 Platform Delivers Ebola Antigens in 15 Days
Dyadic International produced two Bundibugyo ebolavirus antigens in about 15 days using its C1 platform and delivered them for preclinical testing amid an active outbreak in Africa.Biotech Produces Ebola Proteins in Just 15 Days as African Outbreak Intensifies
Dyadic International Inc. (NASDAQ: DYAI) has rapidly developed and produced recombinant protein antigens targeting Bundibugyo ebolavirus, progressing from receipt of the plasmids to purified proteins in approximately 15 days. As the Ebola outbreak in Africa continues, this achievement highlights the speed and potential of Dyadics C1 protein-production platform. Read why one technical analyst believes DYAIs' stock could be positioned for a bullish move.Blood in the Streets: Why I'm Buying Gold Miners, a Peru Tailings Giant, and Two Biotech 10-Baggers This Summer
Contributed Opinion
Newsletter writer Chen Lin shares his view on the current state of the market and shares some stocks on his list. 
Streetwise Key Charts
